Cortexyme announces partnership with parkinson study group and upcoming alzheimer's disease data presentation

South san francisco, calif.--(business wire)--cortexyme, inc. (nasdaq: crtx), a clinical-stage biopharmaceutical company focused on alzheimer's and other degenerative diseases, announced that it has partnered with the parkinson study group (psg) to form an advisory board to leverage the group's expertise and further develop the company's parkinson's disease (pd) program. in addition, cortexyme will present new data further demonstrating the role of porphyromonas gingivalis (p. gingivalis) in th
QNCX Ratings Summary
QNCX Quant Ranking